1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The siRNA Therapeutics Market continues to evolve rapidly, driven by pioneering gene-silencing modalities and the increasing need for targeted therapies across multiple disease categories. Strategic advances in delivery technology, regulatory pathways, and global supply chains have significantly altered the decision landscape for life sciences leaders.
Market Snapshot: siRNA Therapeutics Market
The ThesiRNA Therapeutics Market was valued at USD 2.95 billion in 2024 and is projected to grow to USD 3.25 billion in 2025, at a CAGR of 10.35%, reaching USD 5.33 billion by 2030. This robust trajectory demonstrates increasing industry confidence and expanding adoption for precision gene-silencing solutions. Key drivers include ongoing clinical approvals, innovative drug agents, and advancements in delivery systems that address historical obstacles such as cellular uptake and stability. Adaptive regulatory frameworks, greater investor activity, and evolving patient demographics further contribute to near- and long-term growth.
Scope & Segmentation
- Drug Agent: Includes Givosiran, Inclisiran, Lumasiran, Nedosiran, Patisiran, Vutrisiran, with each agent targeting specific clinical applications and mechanisms of action.
- Delivery Systems: Lipid nanoparticles, peptide delivery systems, and polymer conjugates support precise tissue targeting, improved pharmacokinetics, and scalable manufacturing.
- Route of Administration: Intravenous (IV) and subcutaneous routes balance patient convenience, systemic exposure, and service delivery needs.
- Therapeutic Categories: Cardiovascular disorders, immunological conditions, infectious diseases (bacterial and viral), metabolic disorders, neurological conditions (Alzheimer’s, Parkinson’s), and oncology (hematologic malignancies and multiple solid tumor types).
- End-User: Contract research organizations, hospitals and clinics, pharmaceutical manufacturers, research and academic institutes.
- Regional Coverage: Americas (including the US, Canada, Brazil, and others), Europe Middle East & Africa (Germany, France, Nordics, Gulf countries, and more), and Asia-Pacific (China, Japan, India, Australia, Southeast Asia, among others).
Segment differentiation enables stakeholders to identify high-growth submarkets, optimize resource allocation, and tailor go-to-market strategies to specific clinical needs and regional regulations.
Key Takeaways
- Expanding delivery technologies such as advanced lipid nanoparticles and novel peptide platforms are facilitating wider tissue penetration and durability of response in siRNA therapies.
- Regulatory agencies are increasingly responsive to siRNA innovations, offering adaptive approval processes and clarifying safety benchmarks for earlier market entry.
- Strategic collaborations across biotech startups, research institutes, and pharmaceutical companies are enabling shared access to proprietary technology and accelerating clinical progress.
- Continuous-flow synthesis techniques and supply chain digitalization are improving throughput, quality control, and transparency across the manufacturing lifecycle.
- Segmented growth in oncological, neurological, and rare disease indications reflects a trend toward addressing high unmet clinical needs through orphan drug designations and targeted development.
Tariff Impact on the siRNA Therapeutics Supply Chain
Recent U.S. tariff policies on raw materials and critical delivery substrates are affecting the siRNA supply network, creating incremental cost pressures for specialized lipids, oligonucleotides, and enzymatic reagents. Manufacturers and sponsors are responding by diversifying procurement strategies, pursuing nearshoring or domestic manufacturing, and forming collaborative purchasing groups. Stakeholders also engage in dynamic cost modeling and customs strategies to mitigate project delays and preserve budget margins in multi-year development cycles. These adaptations foster greater supply chain resilience in a shifting regulatory landscape.
Methodology & Data Sources
This analysis is grounded in primary interviews with life sciences executives, clinical leaders, and regulatory experts, as well as secondary research from proprietary datasets, published financials, clinical trial registries, and peer-reviewed literature. Regional insights are supported by reviews of regulatory filings, reimbursement programs, and patent analyses, with findings validated through an internal peer review to ensure accuracy and actionable relevance.
Why This Report Matters
- Offers a comprehensive evaluation of technology trends, pipeline strategies, and segment-specific opportunities to inform actionable decision-making.
- Delivers executive clarity on evolving supply chain, regulatory, and partner dynamics, helping leaders anticipate risk and capture high value segments.
- Enables alignment of investment and R&D priorities with market demand and payer requirements, supporting sustainable growth targets.
Conclusion
As the siRNA Therapeutics Market transitions to broader clinical adoption, stakeholders face an expanding array of choices in therapeutic selection, geographic investment, and collaborative innovation. This report provides clear visibility on these changes, empowering industry leaders to make confident, data-driven decisions.
Table of Contents
1. Preface1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. siRNA Therapeutics Market, by Drug Agent
8.1. Introduction
8.2. Givosiran
8.3. Inclisiran
8.4. Lumasiran
8.5. Nedosiran
8.6. Patisiran
8.7. Vutrisiran
9. siRNA Therapeutics Market, by Delivery Systems
9.1. Introduction
9.2. Lipid Nanoparticles
9.3. Peptide Delivery Systems
9.4. Polymer Conjugates
10. siRNA Therapeutics Market, by Route of Administration
10.1. Introduction
10.2. Intravenous (IV)
10.3. Subcutaneous
11. siRNA Therapeutics Market, by Therapeutic Categories
11.1. Introduction
11.2. Cardiovascular Disorders
11.3. Immunological Disorders
11.4. Infectious Diseases
11.4.1. Bacterial Infections
11.4.2. Viral Infections
11.5. Metabolic Disorders
11.6. Neurological Disorders
11.6.1. Alzheimer's Disease
11.6.2. Parkinson's Disease
11.7. Oncology
11.7.1. Hematologic Malignancies
11.7.1.1. Leukemia
11.7.1.2. Lymphoma
11.7.2. Solid Tumors
11.7.2.1. Breast Cancer
11.7.2.2. Lung Cancer
11.7.2.3. Prostate Cancer
12. siRNA Therapeutics Market, by End-User
12.1. Introduction
12.2. Contract Research Organizations
12.3. Hospitals & Clinics
12.4. Pharmaceutical Companies
12.5. Research & Academic Institutes
13. Americas siRNA Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa siRNA Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific siRNA Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Alnylam Pharmaceuticals Inc.
16.3.2. Alys Pharmaceuticals Inc.
16.3.3. Arbutus Biopharma Corporation
16.3.4. Arcturus Therapeutics, Inc. by Alcobra Ltd.
16.3.5. Aro Biotherapeutics Co.
16.3.6. Arrowhead Pharmaceuticals Inc.
16.3.7. Atalanta Therapeutics
16.3.8. Biocon Ltd.
16.3.9. e-Therapeutics Plc
16.3.10. Eli Lilly and Company
16.3.11. Ionis Pharmaceuticals Inc.
16.3.12. Merck & Co. Inc.
16.3.13. Moderna Therapeutics
16.3.14. Novartis AG
16.3.15. Novo Nordisk A/S
16.3.16. Phio Pharmaceuticals, Inc.
16.3.17. Quark Pharmaceuticals inc.
16.3.18. Risen Pharma Tech Co Ltd
16.3.19. Roche Holding AG
16.3.20. Shanghai Argo Biopharmaceutical Co., Ltd.
16.3.21. Silence Therapeutics plc
16.3.22. Sirius Therapeutics Inc.
16.3.23. Sirnaomics Inc.
16.3.24. Suzhou Sanegene Bio Inc.
16.3.25. Synerk Inc.
16.3.26. Thermo Fisher Scientific Inc.
16.3.27. Vir Biotechnology, Inc.
16.3.28. Wave Life Sciences USA, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. SIRNA THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. SIRNA THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. SIRNA THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. SIRNA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. SIRNA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SIRNA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY GIVOSIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INCLISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LUMASIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEDOSIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PATISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY VUTRISIRAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PEPTIDE DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY POLYMER CONJUGATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SIRNA THERAPEUTICS MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES SIRNA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 71. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 72. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 74. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 75. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 76. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 77. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 78. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 79. CANADA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 80. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 81. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 82. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 84. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 85. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 87. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 88. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 122. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 126. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 128. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 132. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 133. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 135. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 136. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 137. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 138. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 139. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 140. GERMANY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 141. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 142. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 143. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 145. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 146. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 148. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 149. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 150. FRANCE SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 158. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 159. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 160. RUSSIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 162. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 163. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 165. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 166. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 167. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 168. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 169. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 170. ITALY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 171. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 172. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 173. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 174. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 175. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 176. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 177. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 179. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 180. SPAIN SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 210. SOUTH AFRICA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 212. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 213. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 215. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 216. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 217. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 218. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 219. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 220. DENMARK SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 222. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 223. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 225. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 226. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 227. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 228. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 229. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 230. NETHERLANDS SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 232. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 233. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 235. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 236. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 237. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 239. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 240. QATAR SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 242. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 243. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 245. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 246. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 247. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 248. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 249. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 250. FINLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 258. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 259. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 260. SWEDEN SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 269. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 270. NIGERIA SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 271. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 272. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 273. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 274. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 275. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 276. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 277. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 278. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 279. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 280. EGYPT SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 282. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 283. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 284. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 285. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 286. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 287. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 288. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 289. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 290. TURKEY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 291. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 292. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 293. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 294. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 295. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 296. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 297. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 298. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 299. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 300. ISRAEL SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 301. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 302. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 303. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 304. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 305. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 306. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 307. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 308. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 309. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 310. NORWAY SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 311. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 312. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 313. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 314. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 315. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 316. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 317. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 318. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 319. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 320. POLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 322. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 323. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 324. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CATEGORIES, 2018-2030 (USD MILLION)
TABLE 325. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 326. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
TABLE 327. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 328. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 329. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 330. SWITZERLAND SIRNA THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 331. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY DRUG AGENT, 2018-2030 (USD MILLION)
TABLE 332. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY DELIVERY SYSTEMS, 2018-2030 (USD MILLION)
TABLE 333. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 334. ASIA-PACIFIC SIRNA THERAPEUTICS MARKET SIZE, BY THERA
Samples
LOADING...
Companies Mentioned
The companies profiled in this siRNA Therapeutics market report include:- Alnylam Pharmaceuticals Inc.
- Alys Pharmaceuticals Inc.
- Arbutus Biopharma Corporation
- Arcturus Therapeutics, Inc. by Alcobra Ltd.
- Aro Biotherapeutics Co.
- Arrowhead Pharmaceuticals Inc.
- Atalanta Therapeutics
- Biocon Ltd.
- e-Therapeutics Plc
- Eli Lilly and Company
- Ionis Pharmaceuticals Inc.
- Merck & Co. Inc.
- Moderna Therapeutics
- Novartis AG
- Novo Nordisk A/S
- Phio Pharmaceuticals, Inc.
- Quark Pharmaceuticals inc.
- Risen Pharma Tech Co Ltd
- Roche Holding AG
- Shanghai Argo Biopharmaceutical Co., Ltd.
- Silence Therapeutics plc
- Sirius Therapeutics Inc.
- Sirnaomics Inc.
- Suzhou Sanegene Bio Inc.
- Synerk Inc.
- Thermo Fisher Scientific Inc.
- Vir Biotechnology, Inc.
- Wave Life Sciences USA, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 187 |
| Published | May 2025 |
| Forecast Period | 2025 - 2030 |
| Estimated Market Value ( USD | $ 3.25 Billion |
| Forecasted Market Value ( USD | $ 5.33 Billion |
| Compound Annual Growth Rate | 10.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 29 |
